Pliant Therapeutics Stock Statistic Functions Linear Regression
| PLRX Stock | USD 1.33 -0.06 -4.32% |
| Symbol |
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Linear Regression model generates relationship between price series of Pliant Therapeutics and its peer or benchmark and helps predict Pliant Therapeutics future price from its past values.
Pliant Therapeutics Technical Analysis Modules
Most technical analysis of Pliant Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Pliant from various momentum indicators to cycle indicators. When you analyze Pliant charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Pliant Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. As a micro-cap equity, Pliant Therapeutics is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/B of 0.43. Pliant Therapeutics has market cap of 85.41 M, ROE of -64.27%.
Methodology
Unless otherwise specified, financial data for Pliant Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Pliant (USA Stocks:PLRX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Pliant Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Pliant Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Learn to be your own money manager
Tracking Pliant Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Pliant Therapeutics pair trading
Pair trading with Pliant Therapeutics can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Pliant Therapeutics Pair Trading
Pliant Therapeutics Pair Trading Analysis
Identifying correlated replacements for Pliant Therapeutics is particularly important in concentrated portfolios where Pliant Therapeutics represents a large allocation. A poor substitute could introduce unintended factor or sector risks that persist beyond the required waiting period.
Correlation is not causation, but for Pliant Therapeutics it is a practical tool. High correlations between Pliant Therapeutics and a potential addition to the portfolio flag concentrated exposure, while low correlations signal diversification potential.
Correlation analysis and pair evaluation for Pliant Therapeutics can support hedging context. The method can be applied across sectors and broader equity sets.More Resources for Pliant Stock Analysis
Reviewing Pliant Therapeutics commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Pliant Stock:Pliant Therapeutics has market cap of 85.41 M, ROE of -64.27%. See Your Equity Center for portfolio-level analysis. This suggests a position in Pliant Therapeutics within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. Our How to Buy Pliant Stock guide explains the steps to invest in Pliant Therapeutics stock.Analysis related to Pliant Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Understanding Pliant Therapeutics includes distinguishing between market value and book value, where book value reflects Pliant accounting equity. Pliant Therapeutics' market capitalization is 85.41 M. A P/B ratio of 0.43 suggests Pliant Therapeutics trades near or below book value. Intrinsic value is an estimate of underlying worth, separate from trading price and book value. The valuation process compares these measures for perspective.
The concept of value for Pliant Therapeutics differs from its quoted price, since each reflects a different lens. For Pliant Therapeutics, key inputs include a P/B ratio of 0.43, and ROE of -64.27%. Trading price represents the transaction level agreed by market participants.